Hanmi Pharmaceutical said on the 5th that it signed an exclusive supply and license agreement with Viet-Phap to export several of Hanmi Pharmaceutical's fixed-dose hypertension combination drugs to Vietnam.
Viet-Phap is a private pharmaceutical company based in Hanoi, Vietnam, that has imported and supplied orphan drugs and original medicines across various therapeutic areas since its establishment in 2002.
Under the agreement, Hanmi Pharmaceutical will supply finished goods of fixed-dose hypertension combinations to Viet-Phap, and Viet-Phap will handle approvals, distribution and sales in Vietnam. Starting with this contract, the two companies agreed to work closely together to ensure the successful entry of Hanmi Pharmaceutical's key new drugs into the Vietnamese market. Vietnam's hypertension market, serving about 15 million patients, is growing steadily and is worth about $40 million (about 57.8 billion won) annually.
Through this collaboration, the two companies also plan to focus on expanding access to hypertension treatments in Vietnam and improving the local treatment environment.
Park Jae-hyun, CEO of Hanmi Pharmaceutical, said, "With this collaboration with Viet-Phap, we have laid the groundwork for Hanmi Pharmaceutical's flagship hypertension combinations to establish a stable foothold in the Vietnamese market," adding, "We will continue sustained support and cooperation so that local patients can more easily access effective hypertension treatments."
CEO Nguyen Chi Dung of Viet-Phap said, "We will introduce Hanmi Pharmaceutical's next-generation therapies in Vietnam to spur Viet-Phap's growth and contribute to public health," and added, "Beyond hypertension treatments, we hope to continue our collaboration by introducing products in various areas of unmet medical need."
Meanwhile, the company said the agreement was signed at CPHI Worldwide 2025, an international pharmaceutical and biotech exhibition held in Frankfurt, Germany, from the 28th to the 30th of last month.